Antibacterial quinoline derivatives

Details for Australian Patent Application No. 2007328980 (hide)

Owner Janssen Pharmaceutica N.V.

Inventors Guillemont, Jerome Emile Georges; Koul, Anil; Andries, Koenraad Jozef Lodewijk Marcel; Dorange, Ismet

Agent Shelston IP

Pub. Number AU-A-2007328980

PCT Pub. Number WO2008/068266

Priority 06125546.9 06.12.06 EP

Filing date 4 December 2007

Wipo publication date 12 June 2008

International Classifications

C07D 215/227 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

A61K 31/47 (2006.01) - Quinolines

A61P 31/04 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

C07D 215/12 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 215/36 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 407/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

C07D 409/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

Event Publications

23 July 2009 PCT application entered the National Phase

  PCT publication WO2008/068266 Priority application(s): WO2008/068266

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007328981-Substituted pyrimidines and their use as JNK modulators

2007328979-Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases